

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Health Technology Appraisal

Review of TA No. 101; Prostate cancer (hormone-refractory) - docetaxel

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Actavis UK (docetaxel) • Hospira UK(docetaxel) • Medac UK (docetaxel) • Sandoz (docetaxel) • Sanofi (docetaxel) • Teva UK (docetaxel) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Bob Champion Cancer Trust • Cancer Black Care • Cancer Equality • Counsel and Care • Equalities National Council • Everyman • Helen Rollason Heal Cancer Charity • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Great Britain • Muslim Health Network • Orchid • PCaSO – Prostate Cancer Network • Prostate Cancer Charity • Prostate Help Association • Prostate Cancer Support Federation • Specialised Healthcare Alliance • South Asian Health Foundation • Sue Ryder Care • Tenovus <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association for Services to the 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association for Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Baxter Oncology (mitoxantrone) • Hospira UK (mitoxantrone) • Pfizer (mitoxantrone) • Sandoz (mitoxantrone) • Teva UK (mitoxantrone) • Wockhardt UK (mitoxantrone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Prostatic Diseases and Urologic Cancers Group • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute of Health Research

Consultees	Commentators (no right to submit or appeal)
<p>Elderly</p> <ul style="list-style-type: none"> • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Institute of Radiology • British Prostate Group • British Psychosocial Oncology Society • Cancer Network Pharmacists Forum • Cancer Research UK • Pelican Cancer Foundation • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Society of Medicine • Society and College of Radiographers • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Bath and North East Somerset PCT • Department of Health • Pembrokeshire LHB • Welsh Government 	<ul style="list-style-type: none"> • Ovarian & Prostate Cancer Research Trust • Pro-Cancer Research Foundation • Prostate Action (formerly Prostate UK/Prostate Cancer Research Foundation) • Research Institute of the Care of Older People <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Assessment Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.